Instruct patient to report use of MAO inhibitor within the last 14 days prior to initiating therapy.
Patient should avoid activities requiring mental alertness or coordination until drug effects are realized.
Warn patient to not expose extended-release patches to external heat sources while wearing the system, as this may result in potential overdose.
Patients using the device-assisted patch should be advised not to let anyone else activate the device.
This drug may cause pruritus, sweating, nausea, vomiting, xerostomia, asthenia, confusion, dizziness, sedation, urinary retention, or hypotension.
Instruct patient to report absence of pain relief or constipation.
Patient should monitor for signs/symptoms of respiratory depression and hypoventilation, especially during dose initiation or changes, or if patient is febrile.
Before application of the extended-release patch, instruct patient to wash the skin with clear water only. Do not use soap, lotion, alcohol, or oils on the skin prior to application of the extended-release patch.
Apply extended-release patch only to non-irritated skin. If necessary, hair may be clipped (not shaved) from site prior to application.
With long-term use, advise patient against sudden discontinuation of drug.
Instruct patient to avoid alcohol or other CNS depressants during drug therapy.
Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).